Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00581945
First received: December 21, 2007
Last updated: June 28, 2011
Last verified: June 2011

December 21, 2007
June 28, 2011
January 2007
May 2010   (final data collection date for primary outcome measure)
  • Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Baseline, Week 25 and Week 45 ] [ Designated as safety issue: No ]
    Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 was measured by spirometry performed at approximately the same time of day on each visit to avoid diurnal variation. All spirometry calibrations and evaluations followed the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability. A positive change from baseline in FEV1 indicates improvement in lung function.
  • Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted [ Time Frame: Baseline, Week 25 and Week 45 ] [ Designated as safety issue: No ]
    The FEV1 percent predicted expresses FEV1 as a percentage of the "predicted values" for participants of similar characteristics (height, age, sex, and sometimes race and weight). A positive change from baseline in FEV1 % predicted indicates improvement in lung function.
  • Change From Baseline in Forced Vital Capacity (FVC) [ Time Frame: Baseline, Week 25 and Week 45 ] [ Designated as safety issue: No ]
    Forced Vital Capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed by spirometry. A positive change from baseline in FVC indicates improvement in lung function.
  • Change From Baseline in Slow Vital Capacity (SVC) [ Time Frame: Baseline, Week 25 and Week 45 ] [ Designated as safety issue: No ]
    Vital Capacity is the amount of air that can be forcibly exhaled from the lungs after a full inhalation. Slow Vital Capacity (SVC) test is performed by having the patient slowly and completely blow out all of the air from their lungs. A positive change from baseline in SVC indicates improvement in lung function.
  • Change From Baseline in Forced Expiratory Flow 25% to 75% [ Time Frame: Baseline, Week 25 and Week 45 ] [ Designated as safety issue: No ]
    The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry. A positive change from baseline in FEF indicates improvement in lung function.
To explore the impact on pulmonary function of ACZ885 in COPD patients vs. placebo [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00581945 on ClinicalTrials.gov Archive Site
Number of Participants Who Experienced Serious Adverse Events or Discontinued Due to Adverse Events [ Time Frame: Adverse events were collected during the 45 week treatment period and the 12 week follow-up period. ] [ Designated as safety issue: No ]
Safety was assessed by the number of participants with serious adverse events and/or adverse events leading to study discontinuation. A summary of adverse events is presented with this outcome, additional details are provided in the Adverse Events section.
- Assess the impact of multiple doses of ACZ885 over a period of 45 weeks in COPD patients - Assess the safety and tolerability of repeated administration of ACZ885 in COPD patients. - Exploratory outcome: To identify molecular markers of response [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients
A Randomized, Double-blind, Placebo Controlled, Exploratory Study to Assess the Safety and Efficacy of Multiple Doses of ACZ885 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Was to evaluate the safety, tolerability and efficacy of multiple doses of canakinumab (ACZ885) vs. placebo when administered via intravenous infusion (IV), on pulmonary function in patients with COPD

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Chronic Obstructive Pulmonary Disease
  • Drug: Canakinumab
    The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
  • Drug: Placebo
    Matching placebo to ACZ885 administered via intravenous infusion.
  • Experimental: Canakinumab
    Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion. Four weeks later, participants received a dose of 3 mg/kg canakinumab, and another dose of 3 mg/kg two weeks later. Thereafter, participants received doses of 6 mg/kg every four weeks until completion of the 45-week treatment period.
    Intervention: Drug: Canakinumab
  • Placebo Comparator: Placebo
    Participants received a matching placebo intravenous infusion at weeks 1, 5, 7, and thereafter every four weeks until completion of the 45-week treatment period.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
147
May 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and/or female subjects from 40-80 years (inclusive) of age
  • Subjects have a clinical diagnosis of COPD
  • Smokers or Ex-smokers with a smoking history of at least 20 pack years
  • Post-bronchodilator forced expiratory volume in 1 second (FEV1 ) at screening ≤ 50% of the predicted normal value
  • Post-bronchodilator FEV1/FVC ratio < 70%
  • History of at least one treated exacerbation during the 24 months year prior to screening or C-Reactive Protein (CRP) ≥3.47 mg/L,
  • Subjects should have no concomitant other lung disease or significant concomitant medical conditions that would affect the subjects' safety when participating in the study, or that would be expected to impact on the results of the study
  • Female subjects must have been surgically sterilized at least 6 months prior to screening or must be using two forms of contraception, or postmenopausal women
  • Able to provide written informed consent prior to study participation.
  • Able to communicate well with the investigator and comply with the requirements of the study.

Exclusion Criteria:

  • COPD exacerbation(s) requiring treatment within 4 weeks prior to first dosing
  • History of lung reduction surgery
  • Any undiagnosed nodule on chest x-ray
  • Presence of certain medical conditions as specified by the protocol
  • Subjects requiring oral or parenteral corticosteroids equivalent to > 10 mg/day or > 20 mg every other day of prednisone or prednisolone
  • Documented homozygous alpha-1 antitrypsin deficiency.
  • Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.
  • Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.
  • A past medical history of clinically significant electrocardiogram (ECG) abnormalities or a family history of a prolonged QT-interval syndrome.
  • A known hypersensitivity to drugs similar to the study drug.
  • History of immunocompromise, including a positive HIV test result.
  • A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
  • History of drug or alcohol abuse within the 12 months prior to screening or evidence of such abuse as indicated by the laboratory assays conducted during screening.
Both
40 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00581945
CACZ885B2204
No
External Affairs, Novartis
Novartis
Not Provided
Principal Investigator: NOVARTIS Novartis investigator site
Novartis
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP